文献速递青光眼眼底病与葡萄膜炎

通过AAV2-hSyn-NGF基因治疗在青光眼模型中对视网膜神经节细胞的靶向神经保护

Targeted Neuroprotection of Retinal Ganglion Cells Via AAV2-hSyn-NGF Gene Therapy in Glaucoma Models.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

本研究通过携带神经元特异性人突触素启动子的AAV2载体向视网膜神经节细胞递送神经生长因子,在视神经夹伤、微珠诱导高眼压和遗传性青光眼三种模型中评估神经保护作用。最佳注射浓度为每眼1×10¹⁰个载体颗粒,转导效率为46.64%±2.18%,可有效保护视网膜神经节细胞密度、神经纤维层完整性、神经节细胞复合体厚度及功能,且未引发可检测的免疫反应或视网膜结构损伤。

要点

  • 每眼1×10¹⁰个载体颗粒为玻璃体腔注射的最佳浓度。
  • hSyn启动子显著增强对视网膜神经节细胞的靶向特异性,转导效率为46.64%±2.18%。
  • AAV2-hSyn-NGF在三种青光眼模型中均保护视网膜神经节细胞的结构与功能,且未引发可检测的免疫反应或视网膜结构损伤。

核心结论

  • AAV2-hSyn-NGF基因治疗在多种青光眼模型中为视网膜神经节细胞提供安全有效的神经保护策略,是未来青光眼患者临床试验的有前景候选方案。

研究设计与样本

  • 研究在视神经夹伤、微珠诱导高眼压和遗传性青光眼三种模型中玻璃体腔注射AAV2-hSyn-NGF。
  • 采用定量聚合酶链反应和酶联免疫吸附试验确定AAV载体的最佳注射浓度,用流式细胞术监测免疫反应。
  • 以绿色荧光蛋白与视网膜神经节细胞特异性标志物RBPMS共定位定量转导效率,并测量视网膜神经节细胞密度、视网膜神经纤维密度、神经节细胞复合体厚度和正性暗适应阈值反应评估结构与功能。
  • 使用非参数Mann-Whitney U检验或Kruskal-Wallis检验确定统计学显著性(P < 0.05)。

主要发现

  • 玻璃体腔注射AAV载体的最佳浓度为每眼1×10¹⁰个载体颗粒。
  • 使用hSyn启动子显著增强对视网膜神经节细胞的靶向特异性,转导效率为46.64%±2.18%。
  • 给予AAV2-hSyn-NGF在三种青光眼模型中有效保留视网膜神经节细胞密度、神经纤维层完整性和神经节细胞复合体厚度,同时维持视网膜神经节细胞功能。
  • 该基因递送系统未引发可检测的免疫反应或对视网膜的结构损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate the neuroprotective effects of delivering nerve growth factor (NGF) to retinal ganglion cells (RGCs) through adeno-associated virus serotype 2 (AAV2) carrying a neuronal-specific human synapsin (hSyn) promoter. METHODS: AAV2-hSyn-NGF was injected intravitreally in three glaucoma models: optic nerve crush (ONC), microbead-induced ocular hypertension (MB), and genetic glaucoma model (DBA). Quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA) determined the optimal injection concentration of AAV vector. Flow cytometry monitored immune responses. Transduction efficiency was quantified using green fluorescent protein (GFP) co-localization with RGC-specific marker RNA-binding protein with multiple splicing (RBPMS). The RGCs' density, retinal nerve fiber density, ganglion cell complex thickness, and positive scotopic threshold response (pSTR) were measured to assess structural and functional outcomes of the RGCs. Non-parametric Mann-Whitney U tests or Kruskal-Wallis tests were utilized to ascertain the statistical significance (P < 0.05). RESULTS: The optimal concentration of AAV vector for intravitreal injection was determined to be 1 × 1010 vector particles (VPs) per eye. The use of the hSyn promoter significantly enhanced targeting specificity to RGCs, resulting in a transduction efficiency of 46.64% ± 2.18%. Administration of AAV2-hSyn-NGF effectively preserved the RGCs' density, nerve fiber layer integrity, and the thickness of ganglion cell complex, while maintaining the RGCs' function across three glaucoma models. Furthermore, this gene delivery system did not elicit detectable immune responses or structural damage to the retina. CONCLUSIONS: The AAV2-hSyn-NGF gene therapy offers a safe and effective neuroprotective strategy for RGCs across multiple glaucoma models, making it a promising candidate for future clinical trials in patients with glaucoma.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhu X, Qi B, Ren Z, et al. Targeted Neuroprotection of Retinal Ganglion Cells Via AAV2-hSyn-NGF Gene Therapy in Glaucoma Models. Invest Ophthalmol Vis Sci. 2025. PMID: 40244606. doi:10.1167/iovs.66.4.48

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。